Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1244801

NCc1cc(C(=O)Nc2ccc(Nc3cc(-c4cccc5c4oc4ccccc45)ncn3)cc2)ccn1.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2C Q8TBX8 2/20 0.39
LOXL2 Q9Y4K0 5/20 0.39
KDM4E B2RXH2 3/20 0.36
KDM6B O15054 1/20 0.36
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
KDM5C P41229 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM2A Q9Y2K7 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
PIP4K2A P48426 2/20 0.36
PIP4K2B P78356 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PIKFYVE Q9Y2I7 1/20 0.36
ABL1 P00519 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1243428 0.95 PIP4K2C (0.43) PIP4K2CLOXL2KDM4EPIP4K2APIP4K2B
Trifluoroacetic Acid SCHEMBL1244352 0.90 PIP4K2C (0.41) PIP4K2CLOXL2KDM4EPIP4K2APIP4K2B
Trifluoroacetic Acid SCHEMBL1243561 0.90 LOXL2 (0.41) PIP4K2CLOXL2KDM4EPIP4K2APIP4K2B
Trifluoroacetic Acid SCHEMBL1244312 0.89 PIP4K2C (0.45) PIP4K2CLOXL2KDM4EPIP4K2APIP4K2B
Trifluoroacetic Acid SCHEMBL1244552 0.87 PTGS1 (0.43) PIP4K2CKDM4EPIP4K2APIP4K2BPIKFYVE
Trifluoroacetic Acid SCHEMBL4384220 0.87 PIP4K2C (0.39) PIP4K2CLOXL2KDM4EPIP4K2APIP4K2B
Trifluoroacetic Acid SCHEMBL1244929 0.87 LOXL2 (0.37) PIP4K2CLOXL2KDM4EPIP4K2APIP4K2B
SCHEMBL1244420 0.86 PIP4K2C (0.41) PIP4K2CKDM4EPIP4K2APIP4K2BALDH1A1
Trifluoroacetic Acid SCHEMBL1242002 0.86 PIP4K2C (0.43) PIP4K2CKDM4EPIP4K2APIP4K2BALDH1A1
SCHEMBL4382347 0.85 PIP4K2C (0.40) PIP4K2CKDM4EPIP4K2APIP4K2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879853-B2 tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer BAYER SCHERING PHARMA AG (DE) 2011-02-01 US disclosed
EP-1763526-B1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2009-06-24 EP disclosed
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors ATLANTA PHARMA AG (DE) 2007-09-06 US disclosed
EP-1763526-A1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS Altana Pharma AG (DE) 2007-03-21 EP disclosed
WO-2006000589-A1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS ALTANA PHARMA AG (DE) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors CDK2, DCK, DTYMK PIP4K2C 52/4885LOXL2 3815/4885KDM4E 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.